Nomura Asset Management
RPRX icon

Nomura Asset Management’s Royalty Pharma RPRX Stock Holding History

Nomura Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4M Sell
167,680
-4,300
-3% -$224K 0.02% 482
2026
Q1 		$8.25M Sell
171,980
-438
-0.3% -$19.2K 0.02% 476
2025
Q4 		$6.66M Buy
172,418
+24,048
+16% +$917K 0.02% 541
2025
Q3 		$5.23M Buy
148,370
+34,728
+31% +$1.26M 0.01% 584
2025
Q2 		$4.09M Hold
113,642
– – 0.01% 622
2025
Q1 		$3.54M Buy
113,642
+12,000
+12% +$380K 0.01% 641
2024
Q4 		$2.59M Hold
101,642
– – 0.01% 697
2024
Q3 		$2.88M Hold
101,642
– – 0.01% 689
2024
Q2 		$2.68M Sell
101,642
-1,120
-1% -$31K 0.01% 669
2024
Q1 		$3.12M Sell
102,762
-19,137
-16% -$564K 0.01% 645
2023
Q4 		$3.42M Buy
121,899
+28,807
+31% +$792K 0.01% 620
2023
Q3 		$2.53M Sell
93,092
-1,760
-2% -$52.3K 0.01% 659
2023
Q2 		$2.92M Buy
94,852
+9,000
+10% +$305K 0.01% 635
2023
Q1 		$3.09M Buy
85,852
+6,003
+8% +$223K 0.02% 590
2022
Q4 		$3.16M Buy
79,849
+1,010
+1% +$42.2K 0.02% 574
2022
Q3 		$3.17M Buy
78,839
+5,000
+7% +$214K 0.02% 541
2022
Q2 		$3.1M Buy
73,839
+5,000
+7% +$205K 0.02% 590
2022
Q1 		$2.68M Buy
68,839
+830
+1% +$32.6K 0.01% 663
2021
Q4 		$2.71M Buy
68,009
+36,810
+118% +$1.43M 0.01% 672
2021
Q3 		$1.13M Sell
31,199
-46,100
-60% -$1.79M 0.01% 805
2021
Q2 		$3.17M Sell
77,299
-65,961
-46% -$2.81M 0.02% 612
2021
Q1 		$6.25M Buy
143,260
+11,060
+8% +$524K 0.04% 403
2020
Q4 		$6.62M Buy
132,200
+30,600
+30% +$1.3M 0.04% 352
2020
Q3 		$4.28M Buy
+101,600
New +$4.36M 0.03% 418

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Asset Management's RPRX Position: Q2 2026 in Review

Nomura Asset Management reduced its Royalty Pharma (RPRX) stake by 2.5% in Q2 2026, selling an estimated $224K and leaving 167,680 shares worth $9.4M. The position accounts for 0.02% of the portfolio, ranked #482.

Nomura Asset Management first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Nomura Asset Management held 167,680 shares of Royalty Pharma worth $9.4M as of Q2 2026.
  • Nomura Asset Management sold 4,300 Royalty Pharma shares in Q2 2026, an estimated $224K.
  • Royalty Pharma made up 0.02% of Nomura Asset Management's portfolio in Q2 2026, its #482 holding.
  • Nomura Asset Management first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.